Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Pancreatic cancer, one of the most aggressive tumors, has a dismal prognosis because of
the low rates of early identification, fast progression, difficulties following surgery, and the …

Objective: To investigate the outcome of conversion surgery in patients with metastatic
pancreatic cancer (mPDAC) and to identify patients who may benefit from this approach …

Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin,
irinotecan, and oxaliplatin ([m] FOLFIRINOX) as initial treatment for localized pancreatic …

Background The causal pathway between complications after pancreatic cancer resection
and impaired long-term survival remains unknown. The aim of this study was to investigate …

Simple Summary Surgery is the only potential cure for pancreatic ductal adenocarcinoma
and should always be combined with adjuvant chemotherapy or other multimodal treatment …

Importance The total number of patients with pancreatic ductal adenocarcinoma (PDAC)
who receive neoadjuvant chemotherapy (NAC) is increasing. However, the added role of …

Importance Neoadjuvant therapy (NAT) is rarely associated with a complete histopathologic
response in patients with pancreatic ductal adenocarcinoma (PDAC) but results in …

This is a phase II study of PD-1 blockade plus chemoradiotherapy as preoperative therapy
for patients with locally advanced or borderline resectable pancreatic cancer (LAPC or …

Pancreatic cancer (PC) is one of the deadliest malignant tumors, and its resistance to
gemcitabine chemotherapy is the primary reason for poor prognosis in patients. Ubiquitin …